cg-400549
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2009 (NCT01085578)
Timeline
Indications
Mechanism of action
- Enoyl-ACP reductaseINHIBITOR
Q9BJJ9 inhibitor
Enoyl-[acyl-carrier-protein] reductase (FabI) inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O- Mol. weight
- 340.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL488937 ↗
Also known as
- cg400549
- cg400549
- cg400549
- cg 400549
- cg-400549
- cg-400549
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05393856 | Phase 1 | Sep 23, 2019 | CrystalGenomics, Inc., Pharmaceutical Research Associates, Inc. (PRA) |
| NCT01593761 | Phase 2 | Jun 1, 2012 | CrystalGenomics, Inc. |
| NCT01848470 | Phase 1 | May 1, 2010 | CrystalGenomics, Inc. |
| NCT01085578 | Phase 1 | Oct 1, 2009 | CrystalGenomics, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CrystalGenomics, Inc. | For profit | 4 | 4 | 2 | 2009 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1